Pfizer’s Viagra (ingredient: sildenafil), a representative drug to treat erectile dysfunction, has failed to sell even half of generic Viagra copy, “Palpal” of Hanmi Pharm, this year, industry data showed Monday.
According to accumulated prescription sales of the erectile dysfunction-treating ingredients sildenafil and tadalafil in the three quarters this year, Hanmi Pharm’s sildenafil active “Palpal” topped the market with 22.13 billion won ($19.88 million), up 20.4 percent from 18.36 billion won a year earlier. Hanmi’s “Gugu” (ingredient: tadalafil) also saw its revenue increasing 49.2 percent year-on-year to 13.98 billion won in the first three quarters this year, from 9.36 billion won a year earlier.
However, Pfizer’s original drug Viagra was out of its element. Viagra’s accumulated prescription sales grew 10.8 percent this year to 84.3 billion won from 7.61 billion won a year earlier, failing to keep up with Palpal. Tadalafil active original Cialis suffered a 7.6 percent year-on-year sales decline to 7.17 billion won this year.
With approved Viagra copies appearing in the market following the Viagra patent’s expiration, Pfizer came up with new Viagra L, an orally dissolving film, to regain its market dominance. However, the product did not make a meaningful impact because Viagra L was the same drug with a different name of Seoul Pharmaceuticals’ existing pill Vultis.
According to recent data from the Ministry of Food and Drug Safety, Viagra L had zero production between the first quarter and third quarter of 2015, and its output reached only 961 million won in the fourth quarter of the year.
<© Korea Biomedical Review, All rights reserved.>